Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
Publication in refereed journal

替代計量分析
.

其它資訊
摘要BACKGROUND: In advanced non-small cell lung cancer (NSCLC), the effectiveness of standard cytotoxic chemotherapy seems to have reached a 'plateau', and there is a continuous need for new treatments to further improve the prognosis. Cetuximab is a monoclonal antibody targeted at the epidermal growth factor receptor (EGFR) signalling pathway. Basically, it is designed to inhibit the growth and metastasis among other biological processes of cancer. In combination with chemotherapy, it has been evaluated as a first-line treatment for advanced NSCLC in some randomised controlled trials (RCTs), with inconsistent results.
著者Yang Z.-Y., Liu L., Mao C., Wu X.-Y., Huang Y.-F., Hu X.-F., Tang J.-L.
期刊名稱Cochrane Database of Systematic Reviews
出版年份2014
月份1
日期1
卷號11
期次11
出版社John Wiley & Sons Inc.
出版地United States
國際標準期刊號1469-493X
電子國際標準期刊號1361-6137
語言英式英語

上次更新時間 2021-17-02 於 01:57